
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is a strong player in the healthcare industry with a diverse portfolio and a focus on innovative medicines and MedTech. Their recent success with bispecifics and upcoming catalysts in global commercialization, along with a plan to separate their orthopedics business, suggest potential for long-term growth. The company also boasts a commitment to high standards and diversity in management, but ongoing litigations may pose challenges in the near future.
Bears say
Johnson & Johnson is facing significant headwinds from potential loss of exclusivity for certain drugs, as well as potential challenges in its pharmaceutical pipeline gaining traction. The company's focus on M&A also brings along risks related to price paid and integration, and JNJ is currently facing ongoing litigations that could have a negative impact on its financials. Overall, these factors lead to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares